Brokerages Set Palisade Bio, Inc. (NASDAQ:PALI) Target Price at $10.20

Shares of Palisade Bio, Inc. (NASDAQ:PALI) have received an average rating of “Buy” from the nine ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $8.8333.

PALI has been the subject of several recent research reports. LADENBURG THALM/SH SH upgraded shares of Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Weiss Ratings upgraded shares of Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Wall Street Zen cut shares of Palisade Bio from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. HC Wainwright restated a “buy” rating and issued a $2.00 price objective on shares of Palisade Bio in a report on Tuesday. Finally, Oppenheimer set a $7.00 target price on Palisade Bio in a research report on Tuesday.

Hedge Funds Weigh In On Palisade Bio

A number of hedge funds have recently made changes to their positions in the stock. CTC Alternative Strategies Ltd. acquired a new position in shares of Palisade Bio in the first quarter worth approximately $31,000. Bank of America Corp DE increased its position in Palisade Bio by 181.1% during the 1st quarter. Bank of America Corp DE now owns 197,074 shares of the company’s stock valued at $345,000 after purchasing an additional 126,977 shares during the period. Janus Henderson Group PLC increased its position in Palisade Bio by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company’s stock valued at $18,760,000 after purchasing an additional 149,118 shares during the period. ADAR1 Capital Management LLC raised its holdings in Palisade Bio by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 2,264,845 shares of the company’s stock worth $3,963,000 after purchasing an additional 260,000 shares during the last quarter. Finally, Orbimed Advisors LLC raised its holdings in Palisade Bio by 24.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,333,000 shares of the company’s stock worth $4,083,000 after purchasing an additional 461,580 shares during the last quarter. 11.79% of the stock is currently owned by institutional investors.

Palisade Bio Trading Down 5.7%

NASDAQ:PALI opened at $1.97 on Thursday. The stock has a market cap of $341.95 million, a P/E ratio of -1.95 and a beta of 1.50. The stock’s 50-day moving average is $1.94 and its 200-day moving average is $1.91. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.86.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). As a group, equities analysts forecast that Palisade Bio will post -0.25 EPS for the current year.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.